Atea Pharmaceuticals, Inc.
AVIRAtea Pharmaceuticals, Inc. in brief
Atea Pharmaceuticals, Inc. is a listed company in the Biotechnology industry, based in Boston, Massachusetts, USA. Its market value was $343 M on 29 October 2026, which makes it the 14,230th largest listed company in the world and the 2,785th largest in the USA on this site. It employs about 19 people and Jean-Pierre Sommadossi is its chief executive. Its shares trade under the symbol AVIR (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Atea Pharmaceuticals, Inc.
Atea is a Clinical Stage Biopharmaceutical company. It is focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life threatening viral diseases. The company annual revenue is 13.6 million USD and 6,904 employees as on 2019. The headquarters is in USA.
Atea Pharmaceuticals, Inc. timeline
- 2013
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2020
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 30 October 2020; shares registered for exchange trading on 26 October 2020.
Events of Atea Pharmaceuticals, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #1,255 (Jan 2021) · #2,982 (Jan 2022) · #2,911 (Dec 2022) · #3,285 (Jul 2023) · #3,040 (Jan 2024) · #1,285 (Mar 2026) · #2,651 (Aug 2026) · #2,630 (Sep 2026) · #2,789 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 1.2×
- Free cash flow yield
- -35.8%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -57.5%
- Liabilities / assets
- 12.6%
- Revenue growth
- +622.5%
- R&D / revenue
- 47.6%
- Profit per employee
- $-8.3 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-181M | $-158M | — |
| Dec 2024 | — | — | $-193M | $-168M | — |
| Dec 2023 | — | — | $-164M | $-136M | — |
| Dec 2022 | — | — | $-131M | $-116M | — |
| Dec 2021 | $351M | +622.5% | $138M | $121M | 34.5% |
| Dec 2020 | $49M | — | $-11M | $-11M | -22.5% |
| Dec 2019 | — | — | $-15M | $-14M | — |
| Dec 2018 | — | — | $-9M | $-9M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-132M | — | — | $-1.94 | — |
| Dec 2024 | $-136M | — | — | $-2.00 | — |
| Dec 2023 | $-85M | — | — | $-1.63 | — |
| Dec 2022 | $-121M | $2M | $-123M | $-1.39 | — |
| Dec 2021 | $-87M | $0M | $-87M | $1.37 | — |
| Dec 2020 | $297M | $0M | $297M | $-0.51 | — |
| Dec 2019 | $-13M | $0M | $-13M | $-1.39 | — |
| Dec 2018 | $-8M | $0M | $-8M | $-0.90 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-32M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations
- Nov 9, 20268-KCurrent reportMaterial agreement · New financial obligation
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Aug 12, 20268-KCurrent reportResults of operations
- Jun 22, 20268-KCurrent reportShareholder vote
- May 12, 202610-QQuarterly report · period to Mar 2026
- May 12, 20268-KCurrent reportResults of operations
- Apr 27, 2026DEF 14AProxy statement
- Mar 5, 202610-KAnnual report · period to Dec 2025
- Mar 5, 20268-KCurrent reportResults of operations
- Jan 8, 20268-KCurrent reportResults of operations
Official filings of Atea Pharmaceuticals, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-181 M
- Net income
- $-158 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $315 M
- Total liabilities
- $40 M
- Total equity
- $275 M
As of December-2025
Top 100 institutional investors in Atea Pharmaceuticals, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 12,030,704 | +26,640 (+0.22%) | 14.98% | $63 M | Nov 10, 2026 |
| 2 | BlackRock, Inc. | 9,061,530 | +341,453 (+3.92%) | 11.28% | $47 M | Nov 13, 2026 |
| 3 | BML Capital Management, LLC | 6,753,658 | -198,672 (-2.86%) | 8.41% | $35 M | Nov 6, 2026 |
| 4 | Tang Capital Management LLC | 4,814,700 | 0 (0.00%) | 6.00% | $25 M | Nov 16, 2026 |
| 5 | Vanguard Capital Management LLC | 2,906,793 | -58,069 (-1.96%) | 3.62% | $15 M | Nov 13, 2026 |
| 6 | Acadian Asset Management LLC | 2,338,271 | +303,079 (+14.89%) | 2.91% | $12 M | Nov 9, 2026 |
| 7 | Bain Capital Life Sciences Investors, LLC | 2,075,639 | 0 (0.00%) | 2.58% | $11 M | Nov 16, 2026 |
| 8 | Geode Capital Management, LLC | 1,910,289 | -48,146 (-2.46%) | 2.38% | $10 M | Nov 6, 2026 |
| 9 | State Street Corp | 1,626,938 | -25,461 (-1.54%) | 2.03% | $8 M | Nov 12, 2026 |
| 10 | Two Sigma Investments, LP | 1,303,341 | -203,356 (-13.50%) | 1.62% | $7 M | Nov 16, 2026 |
| 11 | Dimensional Fund Advisors LP | 1,300,324 | +809 (+0.06%) | 1.62% | $7 M | Nov 4, 2026 |
| 12 | Renaissance Technologies LLC | 1,092,900 | -38,300 (-3.39%) | 1.36% | $6 M | Nov 12, 2026 |
| 13 | Jpmorgan Chase & Co | 925,284 | -20,634 (-2.18%) | 1.15% | $5 M | Nov 12, 2026 |
| 14 | Northern Trust Corp | 715,769 | -39,470 (-5.23%) | 0.89% | $4 M | Nov 16, 2026 |
| 15 | Vanguard Portfolio Management LLC | 639,968 | +9,783 (+1.55%) | 0.80% | $3 M | Nov 13, 2026 |
| 16 | Charles Schwab Investment Management Inc | 637,551 | +26,944 (+4.41%) | 0.79% | $3 M | Nov 16, 2026 |
| 17 | Morgan Stanley | 556,469 | -163,045 (-22.66%) | 0.69% | $3 M | Nov 13, 2026 |
| 18 | AQR Capital Management LLC | 493,689 | +245,979 (+99.30%) | 0.61% | $3 M | Nov 16, 2026 |
| 19 | Goldman Sachs Group Inc | 477,579 | -53,277 (-10.04%) | 0.59% | $2 M | Nov 16, 2026 |
| 20 | Vanguard Fiduciary Trust Co | 469,723 | -78 (-0.02%) | 0.58% | $2 M | Nov 13, 2026 |
| 21 | CM Management, LLC | 450,000 | +95,000 (+26.76%) | 0.56% | $2 M | Nov 12, 2026 |
| 22 | Rock Springs Capital Management LP | 433,620 | New | 0.54% | $2 M | Nov 16, 2026 |
| 23 | D. E. Shaw & Co., Inc. | 353,494 | +8,308 (+2.41%) | 0.44% | $2 M | Nov 16, 2026 |
| 24 | Banque Pictet & Cie SA | 345,077 | 0 (0.00%) | 0.43% | $2 M | Oct 16, 2026 |
| 25 | Arrowstreet Capital, Limited Partnership | 322,668 | +112,126 (+53.26%) | 0.40% | $2 M | Nov 13, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Rosalind Advisors, Inc. | 280,061 | -790,489 (-73.84%) | 0.35% | $1 M | Nov 16, 2026 |
| 27 | Invesco Ltd. | 254,337 | -12,788 (-4.79%) | 0.32% | $1 M | Nov 12, 2026 |
| 28 | Quantinno Capital Management LP | 251,935 | +9,633 (+3.98%) | 0.31% | $1 M | Nov 13, 2026 |
| 29 | Nuveen, LLC | 247,657 | -36,626 (-12.88%) | 0.31% | $1 M | Nov 10, 2026 |
| 30 | Wellington Management Group LLP | 246,582 | +39,797 (+19.25%) | 0.31% | $1 M | Nov 16, 2026 |
| 31 | Susquehanna International Group, LLP | 245,456 | +231,746 (+1690.34%) | 0.31% | $1 M | Nov 16, 2026 |
| 32 | HSBC Holdings PLC | 240,650 | +19,641 (+8.89%) | 0.30% | $1 M | Nov 16, 2026 |
| 33 | Bank of New York Mellon Corp | 196,724 | +7,272 (+3.84%) | 0.24% | $1 M | Nov 5, 2026 |
| 34 | Barclays PLC | 175,465 | -173,188 (-49.67%) | 0.22% | $1 M | Nov 6, 2026 |
| 35 | Auour Investments LLC | 172,000 | -5,000 (-2.82%) | 0.21% | $1 M | Oct 28, 2026 |
| 36 | Strs Ohio | 171,100 | +53,400 (+45.37%) | 0.21% | $1 M | Oct 30, 2026 |
| 37 | American Century Companies Inc | 170,291 | -366 (-0.21%) | 0.21% | $1 M | Nov 12, 2026 |
| 38 | Millennium Management LLC | 159,884 | -144,727 (-47.51%) | 0.20% | $1 M | Nov 16, 2026 |
| 39 | UBS Group AG | 147,948 | +53,441 (+56.55%) | 0.18% | $1 M | Nov 10, 2026 |
| 40 | Bridgeway Capital Management, LLC | 129,356 | -1,544 (-1.18%) | 0.16% | $1 M | Nov 16, 2026 |
| 41 | Alliancebernstein L.P. | 117,720 | -6,500 (-5.23%) | 0.15% | $1 M | Nov 16, 2026 |
| 42 | State Of Wisconsin Investment Board | 117,357 | -1,400 (-1.18%) | 0.15% | $1 M | Nov 16, 2026 |
| 43 | Price T Rowe Associates Inc /MD/ | 115,808 | 0 (0.00%) | 0.14% | $1 M | Nov 16, 2026 |
| 44 | Bank Of America Corp /de/ | 108,838 | +27,108 (+33.17%) | 0.14% | $1 M | Nov 16, 2026 |
| 45 | Empowered Funds, LLC | 91,256 | New | 0.11% | $0 M | Nov 13, 2026 |
| 46 | Rhumbline Advisers | 88,042 | -3,082 (-3.38%) | 0.11% | $0 M | Nov 10, 2026 |
| 47 | Aldebaran Capital, LLC | 86,068 | -2,112 (-2.40%) | 0.11% | $0 M | Nov 13, 2026 |
| 48 | Nomura Asset Management International Inc. | 70,000 | 0 (0.00%) | 0.09% | $0 M | Nov 16, 2026 |
| 49 | Deutsche Bank AG\ | 61,593 | -8,807 (-12.51%) | 0.08% | $0 M | Nov 6, 2026 |
| 50 | Susquehanna Portfolio Strategies, LLC | 57,502 | -4,571 (-7.36%) | 0.07% | $0 M | Nov 16, 2026 |
| 51 | Russell Investments Group, Ltd. | 55,358 | +466 (+0.85%) | 0.07% | $0 M | Nov 6, 2026 |
| 52 | Trexquant Investment LP | 54,908 | +40,157 (+272.23%) | 0.07% | $0 M | Nov 16, 2026 |
| 53 | Creative Planning | 50,876 | +27,773 (+120.21%) | 0.06% | $0 M | Nov 2, 2026 |
| 54 | WINTON GROUP Ltd | 43,700 | New | 0.05% | $0 M | Nov 12, 2026 |
| 55 | Rangeley Capital, LLC | 41,500 | -2,000 (-4.60%) | 0.05% | $0 M | Nov 16, 2026 |
| 56 | Nano Cap New Millennium Growth Fund L P | 35,000 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 57 | Simplex Trading, LLC | 34,225 | +31,292 (+1066.89%) | 0.04% | $0 M | Nov 4, 2026 |
| 58 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 33,856 | +1,198 (+3.67%) | 0.04% | $0 M | Nov 16, 2026 |
| 59 | MetLife Investment Management, LLC | 30,136 | -9,330 (-23.64%) | 0.04% | $0 M | Nov 16, 2026 |
| 60 | RBF Capital, LLC | 30,000 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 61 | Mercer Global Advisors Inc /adv | 27,650 | -210 (-0.75%) | 0.03% | $0 M | Nov 16, 2026 |
| 62 | Vanguard Global Advisers, LLC | 26,040 | +359 (+1.40%) | 0.03% | $0 M | Nov 13, 2026 |
| 63 | Certified Advisory Corp | 24,500 | 0 (0.00%) | 0.03% | $0 M | Oct 29, 2026 |
| 64 | Spark Investment Management LLC | 24,100 | +7,900 (+48.77%) | 0.03% | $0 M | Nov 13, 2026 |
| 65 | XTX Topco Ltd | 24,055 | New | 0.03% | $0 M | Nov 16, 2026 |
| 66 | BNP Paribas Financial Markets | 23,983 | -54,738 (-69.53%) | 0.03% | $0 M | Nov 12, 2026 |
| 67 | State Board Of Administration Of Florida Retirement System | 22,010 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 68 | Quadrature Capital Ltd | 20,398 | New | 0.03% | $0 M | Nov 13, 2026 |
| 69 | SEI Investments Co | 19,038 | 0 (0.00%) | 0.02% | $0 M | Nov 10, 2026 |
| 70 | Manufacturers Life Insurance Company, The | 17,816 | +118 (+0.67%) | 0.02% | $0 M | Nov 13, 2026 |
| 71 | Engineers Gate Manager LP | 17,077 | +271 (+1.61%) | 0.02% | $0 M | Nov 16, 2026 |
| 72 | Police & Firemen's Retirement System of New Jersey | 16,938 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 73 | New York State Common Retirement Fund | 16,346 | 0 (0.00%) | 0.02% | $0 M | Nov 17, 2026 |
| 74 | Voya Investment Management LLC | 16,242 | 0 (0.00%) | 0.02% | $0 M | Nov 10, 2026 |
| 75 | Bailard, Inc. | 16,100 | 0 (0.00%) | 0.02% | $0 M | Oct 13, 2026 |
| 76 | RFG Advisory, LLC | 14,875 | 0 (0.00%) | 0.02% | $0 M | Nov 3, 2026 |
| 77 | Citadel Advisors LLC | 14,850 | -142,374 (-90.55%) | 0.02% | $0 M | Nov 16, 2026 |
| 78 | China Universal Asset Management Co., Ltd. | 14,634 | +1,898 (+14.90%) | 0.02% | $0 M | Oct 28, 2026 |
| 79 | Wells Fargo & Company/mn | 13,889 | -45,827 (-76.74%) | 0.02% | $0 M | Nov 16, 2026 |
| 80 | Mariner, LLC | 12,848 | New | 0.02% | $0 M | Nov 12, 2026 |
| 81 | Prudential Financial Inc | 12,180 | 0 (0.00%) | 0.02% | $0 M | Nov 16, 2026 |
| 82 | Dynamic Technology Lab Private Ltd | 12,104 | New | 0.02% | $0 M | Nov 13, 2026 |
| 83 | Sunpointe, LLC | 11,943 | 0 (0.00%) | 0.01% | $0 M | Oct 22, 2026 |
| 84 | ProShare Advisors LLC | 11,685 | -222 (-1.86%) | 0.01% | $0 M | Oct 29, 2026 |
| 85 | Wealth Enhancement Advisory Services, LLC | 11,266 | New | 0.01% | $0 M | Oct 13, 2026 |
| 86 | Blair William & Co/il | 11,025 | -300 (-2.65%) | 0.01% | $0 M | Nov 10, 2026 |
| 87 | Fox Run Management, L.L.C. | 10,245 | New | 0.01% | $0 M | Nov 12, 2026 |
| 88 | M&T Bank Corp | 10,130 | New | 0.01% | $0 M | Nov 10, 2026 |
| 89 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 9,207 | +6,888 (+297.02%) | 0.01% | $0 M | Nov 16, 2026 |
| 90 | Blue Trust, Inc. | 8,700 | 0 (0.00%) | 0.01% | $0 M | Oct 15, 2026 |
| 91 | Legal & General Group Plc | 7,082 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 92 | Citigroup Inc | 6,754 | -27,860 (-80.49%) | 0.01% | $0 M | Nov 4, 2026 |
| 93 | Group One Trading LLC | 6,538 | +6,398 (+4570.00%) | 0.01% | $0 M | Nov 10, 2026 |
| 94 | Ameritas Investment Partners, Inc. | 5,914 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 95 | FNY Investment Advisers, LLC | 5,000 | 0 (0.00%) | 0.01% | $0 M | Oct 16, 2026 |
| 96 | PNC Financial Services Group, Inc. | 4,544 | +1,759 (+63.16%) | 0.01% | $0 M | Nov 6, 2026 |
| 97 | Arax Advisory Partners | 4,484 | +260 (+6.16%) | 0.01% | $0 M | Nov 12, 2026 |
| 98 | Versant Capital Management, Inc | 4,397 | +177 (+4.19%) | 0.01% | $0 M | Oct 2, 2026 |
| 99 | Mirae Asset Global Investments Co., Ltd. | 4,099 | +520 (+14.53%) | 0.01% | $0 M | Oct 29, 2026 |
| 100 | Royal Bank Of Canada | 3,790 | +572 (+17.78%) | 0.00% | $0 M | Nov 16, 2026 |
Mutual funds holding Atea Pharmaceuticals, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Growth Company FundFidelity Management & Research Company LLC | 3.10 M | $14 M | 3.9% | 0.01% | +21% | May 31, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 2.03 M | $9 M | 2.5% | <0.01% | −14% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.84 M | $9 M | 2.3% | 0.01% | +6.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Growth Company K6 FundFidelity Management & Research Company LLC | 1.22 M | $6 M | 1.5% | 0.02% | −0.5% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 865,318 | $4 M | 1.1% | <0.01% | +7.0% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 771,325 | $4 M | 0.96% | 0.01% | +12% | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Growth Company FundFidelity Management & Research Company LLC | 733,900 | $3 M | 0.91% | 0.01% | +22% | May 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 669,481 | $3 M | 0.83% | 0.02% | +13% | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC | 613,370 | $3 M | 0.76% | 0.05% | −1.2% | May 29, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 437,948 | $2 M | 0.55% | 0.02% | −4.8% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 358,829 | $2 M | 0.45% | <0.01% | +1.8% | May 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 349,976 | $2 M | 0.44% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 345,893 | $2 M | 0.43% | <0.01% | −1.6% | May 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 313,724 | $1 M | 0.39% | <0.01% | −12% | May 31, 2026 |
| 🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC | 287,662 | $1 M | 0.36% | 0.03% | +21% | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 263,930 | $1 M | 0.33% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 JPMorgan U.S. Small Company FundJ.P. Morgan Investment Management Inc. | 243,540 | $1 M | 0.30% | 0.10% | −6.7% | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 238,228 | $1 M | 0.30% | 0.07% | +35% | Jun 30, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 234,809 | $1 M | 0.29% | 0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 180,290 | $1 M | 0.22% | <0.01% | −3.3% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 172,263 | $1 M | 0.21% | 0.01% | +13% | Jul 31, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 153,768 | $1 M | 0.19% | <0.01% | −0.8% | May 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 151,732 | $1 M | 0.19% | 0.03% | +2.5% | May 31, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 148,672 | $1 M | 0.19% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds | 142,812 | $1 M | 0.18% | 0.08% | −0.1% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 138,233 | $1 M | 0.17% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 131,975 | $1 M | 0.16% | 0.01% | +25% | Jun 30, 2026 |
| 🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc. | 125,715 | $1 M | 0.16% | 0.04% | −5.7% | Jun 30, 2026 |
| 🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC | 110,737 | $1 M | 0.14% | <0.01% | −1.5% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 107,781 | $1 M | 0.13% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Small Cap Value FundNorthern Trust Investments, Inc. | 104,395 | $0 M | 0.13% | 0.07% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 98,939 | $0 M | 0.12% | 0.02% | +14% | Jun 30, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 94,351 | $0 M | 0.12% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 92,800 | $0 M | 0.12% | 0.29% | −16% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 89,888 | $0 M | 0.11% | 0.01% | no change | Jul 31, 2026 |
| 🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc. | 82,125 | $0 M | 0.10% | 0.24% | +18% | May 31, 2026 |
| 🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP | 81,300 | $0 M | 0.10% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 70,280 | $0 M | 0.09% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Nomura Healthcare FundDelaware Management Company | 70,000 | $0 M | 0.09% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC | 69,618 | $0 M | 0.09% | <0.01% | −28% | May 31, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 65,990 | $0 M | 0.08% | 0.02% | +4.6% | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 58,155 | $0 M | 0.07% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Invesco BuyBack AchieversTM ETFInvesco Capital Management LLC | 57,412 | $0 M | 0.07% | 0.01% | +25% | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc. | 56,800 | $0 M | 0.07% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 54,498 | $0 M | 0.07% | <0.01% | −10.0% | Jul 31, 2026 |
| 🇺🇸 LVIP JPMorgan Small Cap Core FundLincoln Financial Investments Corporation | 54,347 | $0 M | 0.07% | 0.10% | −5.4% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 54,047 | $0 M | 0.07% | 0.02% | +4.7% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 52,533 | $0 M | 0.07% | <0.01% | −9.2% | May 31, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 51,459 | $0 M | 0.06% | <0.01% | −24% | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 48,000 | $0 M | 0.06% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 47,410 | $0 M | 0.06% | <0.01% | +1.0% | May 31, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 45,730 | $0 M | 0.06% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 45,000 | $0 M | 0.06% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 42,851 | $0 M | 0.05% | <0.01% | −25% | Jun 30, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 41,180 | $0 M | 0.05% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 36,692 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 35,845 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vy Jpmorgan Small Cap Core Equity PortfolioVoya Investments, LLC | 35,773 | $0 M | 0.04% | 0.05% | −5.0% | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 33,880 | $0 M | 0.04% | 0.01% | +12% | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 34,065 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 31,847 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 JPMorgan Small Cap Value PortfolioBrighthouse Investment Advisers, LLC | 30,925 | $0 M | 0.04% | 0.04% | −14% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 30,676 | $0 M | 0.04% | 0.01% | no change | May 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 30,304 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 27,358 | $0 M | 0.03% | <0.01% | +11% | Jul 31, 2026 |
| 🇺🇸 Small Cap Value FundThe Variable Annuity Life Insurance Company | 25,608 | $0 M | 0.03% | 0.05% | −11% | May 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 23,200 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 22,588 | $0 M | 0.03% | <0.01% | −1.4% | Jun 30, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 21,416 | $0 M | 0.03% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage SMID Cap Fund, Inc.BlackRock Advisors, LLC | 20,922 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 18,297 | $0 M | 0.02% | <0.01% | −0.8% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 17,888 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 16,803 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP | 16,361 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 16,504 | $0 M | 0.02% | 0.01% | +23% | Jun 30, 2026 |
| 🇺🇸 Nationwide Bailard Small Cap Value FundNATIONWIDE FUND ADVISORS | 16,100 | $0 M | 0.02% | 0.06% | new | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 15,830 | $0 M | 0.02% | 0.03% | +26% | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 15,000 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 14,244 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage SMID Cap V.I. FundBlackRock Advisors, LLC | 14,243 | $0 M | 0.02% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 13,884 | $0 M | 0.02% | <0.01% | +16% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 13,029 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/Common Stock Index PortfolioEquitable Investment Management Group, LLC | 12,500 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 11,600 | $0 M | 0.01% | <0.01% | −9.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 11,445 | $0 M | 0.01% | 0.01% | +7.2% | Jul 31, 2026 |
| 🇺🇸 SA Multi-Managed Small Cap PortfolioSunAmerica Asset Management, LLC | 11,480 | $0 M | 0.01% | 0.04% | −9.1% | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 11,130 | $0 M | 0.01% | 0.01% | +12% | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Equity ETFAmerican Century ETF Trust | 11,053 | $0 M | 0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 10,817 | $0 M | 0.01% | 0.01% | +20% | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 10,669 | $0 M | 0.01% | 0.01% | +19% | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 10,228 | $0 M | 0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Invesco Russell 2000 Dynamic Multifactor ETFInvesco Capital Management LLC | 9,805 | $0 M | 0.01% | 0.02% | new | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP | 9,202 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 8,884 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 8,300 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 7,814 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 7,400 | $0 M | <0.01% | <0.01% | −21% | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 7,314 | $0 M | <0.01% | <0.01% | +1.8% | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 7,281 | $0 M | <0.01% | <0.01% | +1.6% | Jul 31, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 7,042 | $0 M | <0.01% | 0.01% | +35% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Atea Pharmaceuticals, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Bruce PolskyDirector | Option exercise | +18,252 | $1.240 | $23 K | 176,832 | Form 4 |
| filed | Bruce PolskyDirector | Sell | -18,252 | $3.950 | $72 K | 158,580 | Form 4 |
| filed | Bruce PolskyDirector | Option exercise | +8,720 | $1.240 | $11 K | 167,300 | Form 4 |
| filed | Bruce PolskyDirector | Sell | -8,720 | $4.032 | $35 K | 158,580 | Form 4 |
| filed | Bruce PolskyDirector | Option exercise | +48,028 | $1.240 | $60 K | 172,834 | Form 4 |
| filed | Bruce PolskyDirector | Sell | -14,254 | $4.268 | $61 K | 158,580 | Form 4 |
| filed | Franklin M. BergerDirector | Option exercise | +29,600 | — | — | 536,097 | Form 4 |
| filed | Bruce PolskyDirector | Option exercise | +29,600 | — | — | 124,806 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Atea Pharmaceuticals, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2025 | Q4 2025 | $0M |
| Q3 2025 | Q3 2025 | $11.4M |
Trading halts
- 2026-07-28 10:55 UTC, code T3, resumed 11:30 UTC
Fails to deliver
- : 566 shares at $4.27
- : 1,237 shares at $5.26
- : 80 shares at $5.27
- : 2 shares at $4.81
- : 72 shares at $4.87
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Atea Pharmaceuticals, Inc. scorecard#
Passes 4 of the 13 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 29, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.2×Price to book 1.2× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-35.9%Free cash flow is -35.9% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.94 vs -2.00Diluted EPS -1.94 in fiscal 2025 against -2.00 the year before (report's currency).
- ✗Net income higher than five years earlier-$158 M-$158 M in fiscal 2025 against -$11 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$158 MNet income -$158 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-44.3%-44.3% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities7.8×Current ratio 7.82 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns2 of 2
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year-3.3%Diluted shares down 3.3% in fiscal 2025.
- ✓Dividends and buybacks above 3% of the market value7.4%Dividends and buybacks were 7.4% of the market value.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Atea Pharmaceuticals, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | — | — | — | — | 351+622%100% | 49—100% | — | — | |
| Research and development | 148+2.7%— | 144+26.1%— | 114+39.4%— | 82−51.0%— | 167+340%47.6% | 38+274%78.2% | 10+52.4%— | 6.7—— | |
| General and administrative | 33−32.7%— | 49−2.1%— | 50+2.5%— | 49+6.4%— | 46+112%13.0% | 22+388%44.5% | 4.4+58.4%— | 2.8—— | |
| Operating expenses | 181−6.3%— | 193+17.5%— | 164+25.7%— | 131−38.7%— | 213+257%60.6% | 60+308%123% | 15+54.1%— | 9.5—— | |
| Operating income | −181—— | −193—— | −164—— | −131−194%— | 138—39.4% | −11—−22.7% | −15—— | −9.5—— | |
| Income before tax | −165—— | −167—— | −135—— | −119−186%— | 139—39.4% | −11—−22.5% | −14—— | — | |
| Income tax | −6.2−766%— | 0.9−9.1%— | 1.0—— | −3.6−121%— | 17—5.0% | — | — | — | |
| Net income including minority interests | −158—— | −168—— | −136—— | −116−196%— | 121—34.5% | −11—−22.5% | −14—— | −9.1—— | |
| Net income attributable to shareholders | −158—— | −168—— | −136—— | −116−196%— | 121—34.5% | −11—−22.5% | −14—— | −9.1—— | |
| Earnings per share, basic | -1.94—— | -2.00—— | -1.63—— | -1.39−195%— | 1.46—— | -0.51—— | -1.39—— | -0.90—— | |
| Earnings per share, diluted | -1.94—— | -2.00—— | -1.63—— | -1.39−201%— | 1.37—— | -0.51—— | -1.39—— | -0.90—— | |
| Shares, weighted average (basic) | 81−3.3%— | 84+1.0%— | 83+0.2%— | 83+0.5%— | 83+284%— | 22+114%— | 10—— | — | |
| Shares, weighted average (diluted) | 81−3.3%— | 84+1.0%— | 83+0.2%— | 83−5.7%— | 88+309%— | 22+114%— | 10+0.5%— | 10—— | |
| Balance sheet | |||||||||
| Cash and cash equivalents | 96+47.9%30.4% | 65−55.0%13.9% | 144−23.7%24.2% | 188−75.3%28.3% | 764−10.1%98.9% | 850r850+3825%98.4% | 22−37.2%98.1% | 34—— | |
| Short-term investments | 206−47.2%65.4% | 390−10.2%83.9% | 434−5.2%73.0% | 458—68.7% | — | — | — | — | |
| Other current assets | 9.2+20.0%2.9% | 7.6−38.2%1.6% | 12−13.1%2.1% | 14+77.0%2.1% | 8.0+6.4%1.0% | 7.5+2930%0.9% | 0.2—1.1% | — | |
| Current assets | 311−32.7%98.7% | 462−21.7%99.5% | 590−10.7%99.2% | 661−14.4%99.1% | 772−10.5%99.9% | 863+3841%100.0% | 22—99.3% | — | |
| Property, plant and equipment | 0.5−47.7%0.1% | 0.9−32.3%0.2% | 1.3−24.4%0.2% | 1.7+7313%0.3% | 0.0−52.1%0.0% | 0.0+17.1%0.0% | 0.0—0.2% | — | |
| Right-of-use (leased) assets | 0.6−49.0%0.2% | 1.2−32.0%0.3% | 1.8−23.5%0.3% | 2.4+1384%0.4% | 0.2—0.0% | — | — | — | |
| Total assets | 315−32.2%100% | 465−21.9%100% | 595−10.8%100% | 667−13.7%100% | 773−10.5%100% | 864+3813%100% | 22—100% | — | |
| Accounts payable | 13+190%4.1% | 4.5+4.8%1.0% | 4.3+66.7%0.7% | 2.6−43.7%0.4% | 4.5+7457%0.6% | 0.1−89.1%0.0% | 0.5—2.5% | — | |
| Current liabilities | 40+114%12.6% | 19−42.5%4.0% | 32+75.2%5.4% | 18−67.5%2.8% | 57−82.0%7.4% | 316+12869%36.6% | 2.4—11.0% | — | |
| Lease liabilities (non-current) | 0−100%0.0% | 0.8−48.7%0.2% | 1.6−31.7%0.3% | 2.4—0.4% | — | — | — | — | |
| Total liabilities | 40+54.2%12.6% | 26−35.1%5.6% | 40+52.2%6.7% | 26−58.4%3.9% | 63−80.1%8.1% | 316+12383%36.6% | 2.5—11.5% | — | |
| Retained earnings | −523—−166% | −364—−78.4% | −196—−32.9% | −60−207%−9.0% | 56—7.2% | −65—−7.5% | −54—−246% | — | |
| Shareholders' equity | 275−37.2%87.4% | 439−21.0%94.4% | 555−13.3%93.3% | 641−9.8%96.1% | 710+29.6%91.9% | 548—63.4% | −50—−225% | −36—— | |
| Total liabilities and equity | 315−32.2%100% | 465−21.9%100% | 595−10.8%100% | 667−13.7%100% | 773−10.5%100% | 864+3813%100% | 22—100% | — | |
| Shares outstanding | 78−7.5%— | 84+1.2%— | 83+0.2%— | 83+0.2%— | 83+0.8%— | 82+717%— | 10—— | — | |
| Cash-flow statement | |||||||||
| Depreciation and amortization | 0.40.0%— | 0.40.0%— | 0.4+60.0%— | 0.3+797%— | 0.0+52.6%0.0% | 0.0+11.8%0.0% | 0.00.0%— | 0.0—— | |
| Share-based compensation | 21−60.0%— | 52+4.7%— | 49+5.8%— | 47+17.9%— | 40+431%11.3% | 7.5+1095%15.3% | 0.6+50.7%— | 0.4—— | |
| Cash from operating activities | −132—— | −135—— | −85—— | −121—— | −87−129%−24.8% | 297—610% | −13—— | −7.9—— | |
| Capital expenditure | — | — | — | −1.9—— | −0.0—−0.0% | −0.0—−0.1% | −0.0—— | −0.0—— | |
| Cash from investing activities | 189+236%— | 56+39.2%— | 40—— | −455—— | −0.0—−0.0% | −0.0—−0.1% | −0.0—— | −0.0—— | |
| Shares issued | — | — | — | — | 1.5+5326%0.4% | 0.0—0.1% | — | 0.1—— | |
| Shares bought back | −26—— | 0—— | — | — | — | — | — | — | |
| Cash from financing activities | −26−9742%— | 0.3+3.9%— | 0.3−30.5%— | 0.4−74.7%— | 1.5−99.7%0.4% | 532—1093% | — | 27—— | |
| Change in cash | 31—— | −79—— | −45—— | −576—— | −86−110%−24.3% | 828—1703% | −13−166%— | 20—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 144+14.6%— | 27−29.4%— | 28−12.8%— | 41+39.0%— | 48*+86.3%— | 38+46.6%— | 32−7.0%— | 30−48.6%— | 26*−26.7%— | 26—— | 35—— | 58—— | 35*—— | |
| General and administrative | 28−28.7%— | 6.9−4.1%— | 6.9−23.4%— | 6.9−27.3%— | 7.1*−46.7%— | 7.2−34.6%— | 9.1−25.8%— | 9.5−22.7%— | 13*+15.8%— | 11—— | 12—— | 12—— | 12*—— | |
| Operating expenses | 172+4.3%— | 34−25.4%— | 35−15.1%— | 48+23.0%— | 55*+40.8%— | 46+22.5%— | 41−11.9%— | 39−44.1%— | 39*−16.2%— | 37—— | 47—— | 70—— | 47*—— | |
| Operating income | −172—— | −34—— | −35—— | −48—— | −55*—— | −46—— | −41—— | −39—— | −39*—— | −37—— | −47—— | −70—— | −47*—— | |
| Income before tax | −162—— | −32—— | −33—— | −45—— | −52*—— | −42—— | −37—— | −34—— | −33*—— | −31—— | −40—— | −63—— | −39*—— | |
| Income tax | −6.7−901%— | 0.0−80.6%— | 0.0−88.4%— | 0.1−75.4%— | −6.8*−3108%— | 0.2−13.3%— | 0.2−14.8%— | 0.2−12.1%— | 0.2*−35.5%— | 0.2—— | 0.2—— | 0.2—— | 0.3*—— | |
| Net income including minority interests | −155—— | −32*—— | −33*—— | −45—— | −45*—— | −42*—— | −37*—— | −34—— | −34*—— | −31*—— | −41*—— | −63—— | −39*—— | |
| Net income attributable to shareholders | −155—— | −32—— | −33—— | −45—— | −45*—— | −42—— | −37—— | −34—— | −34*—— | −31—— | −41—— | −63—— | −39*—— | |
| Earnings per share, basic | — | -0.40—— | -0.41—— | -0.57—— | — | -0.53—— | -0.44—— | -0.40—— | — | -0.37—— | -0.48—— | -0.75—— | — | |
| Earnings per share, diluted | — | -0.40—— | -0.41—— | -0.57—— | — | -0.53—— | -0.44—— | -0.40—— | — | -0.37—— | -0.48—— | -0.75—— | — | |
| Shares, weighted average (basic) | 80+1.5%— | 80+1.5%— | 80−4.4%— | 79−7.0%— | — | 79−6.4%— | 84−0.6%— | 85+1.5%— | — | 84—— | 84—— | 84—— | — | |
| Shares, weighted average (diluted) | 80+1.5%— | 80+1.5%— | 80−4.4%— | 79−7.0%— | — | 79−6.4%— | 84−0.6%— | 85+1.5%— | — | 84—— | 84—— | 84—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 98—48.8% | 98+26.6%48.8% | 77−12.7%33.0% | 79−33.6%29.7% | 96+47.9%30.4% | 77−21.4%22.6% | 88−64.0%22.4% | 119−25.8%27.1% | 65−55.0%13.9% | 98—20.1% | 243—47.7% | 161—29.1% | 144—24.2% | |
| Short-term investments | 93—46.5% | 93−63.0%46.5% | 143−51.1%61.5% | 177−42.3%66.2% | 206−47.2%65.4% | 252−34.4%73.5% | 292+12.8%74.6% | 306−19.6%69.6% | 390−10.2%83.9% | 384—78.3% | 259—50.7% | 381—68.8% | 434—73.0% | |
| Other current assets | 9.1—4.5% | 9.1+32.8%4.5% | 9.2+56.2%4.0% | 7.2−13.1%2.7% | 9.2+20.0%2.9% | 6.8+66.8%2.0% | 5.9+41.8%1.5% | 8.3+13.7%1.9% | 7.6−38.2%1.6% | 4.1—0.8% | 4.2—0.8% | 7.3—1.3% | 12—2.1% | |
| Current assets | 200—99.8% | 200−40.4%99.8% | 229−40.7%98.4% | 263−39.3%98.5% | 311−32.7%98.7% | 336−31.0%98.0% | 386−23.8%98.5% | 434−21.0%98.6% | 462−21.7%99.5% | 487—99.2% | 506—99.2% | 549—99.2% | 590—99.2% | |
| Property, plant and equipment | 0.1—0.1% | 0.1−74.2%0.1% | 0.2−62.6%0.1% | 0.4−54.1%0.1% | 0.5−47.7%0.1% | 0.6−42.6%0.2% | 0.7−38.5%0.2% | 0.8−35.1%0.2% | 0.9−32.3%0.2% | 1.0—0.2% | 1.1—0.2% | 1.2—0.2% | 1.3—0.2% | |
| Right-of-use (leased) assets | 0.2—0.1% | 0.2−79.6%0.1% | 0.3−66.0%0.1% | 0.5−56.3%0.2% | 0.6−49.0%0.2% | 0.8−43.3%0.2% | 0.9−38.8%0.2% | 1.1−35.1%0.2% | 1.2−32.0%0.3% | 1.4—0.3% | 1.5—0.3% | 1.7—0.3% | 1.8—0.3% | |
| Total assets | 201—100% | 201−41.5%100% | 232−40.7%100% | 267−39.3%100% | 315−32.2%100% | 343−30.1%100% | 392−23.3%100% | 440−20.4%100% | 465−21.9%100% | 491—100% | 510—100% | 553—100% | 595—100% | |
| Accounts payable | 4.8—2.4% | 4.8+37.8%2.4% | 10+13.7%4.3% | 9.4+27.9%3.5% | 13+190%4.1% | 3.5−39.2%1.0% | 8.8+61.7%2.3% | 7.4−65.1%1.7% | 4.5+4.8%1.0% | 5.8—1.2% | 5.5—1.1% | 21—3.8% | 4.3—0.7% | |
| Current liabilities | 25—12.5% | 25+24.0%12.5% | 28+39.8%12.1% | 33+53.4%12.5% | 40+114%12.6% | 20−19.9%5.9% | 20−24.4%5.1% | 22−47.4%4.9% | 19−42.5%4.0% | 25—5.1% | 27—5.2% | 41—7.5% | 32—5.4% | |
| Lease liabilities (non-current) | — | — | — | — | 0−100%0.0% | 0.2−79.6%0.1% | 0.4−65.9%0.1% | 0.6−56.1%0.1% | 0.8−48.7%0.2% | 1.0—0.2% | 1.2—0.2% | 1.4—0.3% | 1.6—0.3% | |
| Total liabilities | — | — | — | — | 40+54.2%12.6% | 27−16.2%7.9% | 27−19.8%6.9% | 29−40.6%6.6% | 26−35.1%5.6% | 32—6.6% | 34—6.6% | 49—8.8% | 40—6.7% | |
| Retained earnings | −633—−315% | −633—−315% | −601—−259% | −568—−213% | −523—−166% | −478—−139% | −436—−111% | −398—−90.6% | −364—−78.4% | −331—−67.4% | −300—−58.7% | −259—−46.8% | −196—−32.9% | |
| Shareholders' equity | 176—87.5% | 176−44.4%87.5% | 204−44.0%87.9% | 234−43.1%87.5% | 275−37.2%87.4% | 316−31.1%92.1% | 364−23.5%93.1% | 411−18.5%93.4% | 439−21.0%94.4% | 459—93.4% | 476—93.4% | 504—91.2% | 555—93.3% | |
| Total liabilities and equity | 201—100% | 201−41.5%100% | 232−40.7%100% | 267−39.3%100% | 315−32.2%100% | 343−30.1%100% | 392−23.3%100% | 440−20.4%100% | 465−21.9%100% | 491—100% | 510—100% | 553—100% | 595—100% | |
| Shares outstanding | 80—— | 80+2.8%— | 80−1.1%— | 80−6.5%— | 78−7.5%— | 78−7.5%— | 81−3.9%— | 86+1.6%— | 84+1.2%— | 84—— | 84—— | 84—— | 83—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.40.0%— | 0.1*0.0%— | 0.1*0.0%— | 0.10.0%— | 0.1*0.0%— | 0.1*0.0%— | 0.1*0.0%— | 0.10.0%— | 0.1*0.0%— | 0.1*—— | 0.1*—— | 0.1—— | 0.1*—— | |
| Share-based compensation | 15−50.2%— | 3.5−23.2%— | 3.4−27.6%— | 3.7−46.4%— | 4.6*−67.9%— | 4.5−62.9%— | 4.7−63.3%— | 7.0−44.8%— | 14*+17.6%— | 12—— | 13—— | 13—— | 12*—— | |
| Cash from operating activities | −141—— | −29*—— | −37*—— | −46—— | −28*—— | −40*—— | −33*—— | −31—— | −30*—— | −23*—— | −42*—— | −40—— | −22*—— | |
| Cash from investing activities | 161+15.8%— | 50*+21.2%— | 34*+124%— | 30−65.3%— | 47*—— | 41*—— | 15*−87.7%— | 86+50.7%— | −3.4*−112%— | −122*—— | 125*—— | 57—— | 28*—— | |
| Shares bought back | — | — | — | — | 0*—— | −11*—— | — | — | — | — | — | — | — | |
| Cash from financing activities | 0.5—— | 0.2*—— | 0*—— | 0.3—— | 0*—— | −11*−9762%— | −14*—— | −0.3−331%— | 0*—— | 0.1*—— | 0*—— | 0.2—— | 0*—— | |
| Change in cash | 21—— | 21*—— | −2.8*—— | −16−130%— | 18*—— | −10*—— | −32*−138%— | 55+220%— | −34*−669%— | −145*—— | 82*—— | 17—— | 5.9*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Atea Pharmaceuticals, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Jean-Pierre Sommadossi | $3.4 M | $3.6 M | $1.6 M | $9 (peers $125) |
| 2024Jean-Pierre Sommadossi | $4.2 M | $4.3 M | $1.8 M | $8 (peers $93) |
| 2023Jean-Pierre Sommadossi | $5.9 M | $3.4 M | $1.9 M | $7 (peers $94) |
| 2022Jean-Pierre Sommadossi | $5.9 M | $705 K | $1.9 M | $12 (peers $90) |
| 2021Jean-Pierre Sommadossi | $34.1 M | −$1.5 M | $8.0 M | $21 (peers $100) |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Atea Pharmaceuticals, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 2 · Material agreement 2 · New debt 1 · Shareholder vote 3 · Results announced 16
| Filed | What happened | Filing |
|---|---|---|
| Material agreementNew debt | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officersMaterial agreementResults announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
4 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Atea Pharmaceuticals, Inc.#
$20 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues.
- Health Issues2 reports
Lobbying firms hired in 2025
JEFFREY J. KIMBELL & ASSOCIATES, INC. $20 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $30 K | — | 3 |
| 2025 | $20 K | — | 2 |
| 2024 | $60 K | — | 6 |
| 2023 | $320 K | — | 12 |
| 2022 | $230 K | — | 10 |
| 2021 | $190 K | — | 8 |
| 2020 | $150 K | — | 6 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Atea Pharmaceuticals” and “Atea Pharmaceuticals, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Atea Pharmaceuticals, Inc.#
1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $162 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Associate Director, Quality ControlChemists | 1 | $162 K |
Where: Boston, MA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 1 | 1 | $162 K | 1 |
| FY2020 | 1 | 1 | $160 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Atea Pharmaceuticals, Inc.
How Atea Pharmaceuticals, Inc. compares in Biotechnology
- Market cap$343 M · higher than 53% of 726
- Revenue growth622.5% · higher than 95% of 438
- Price / book1.2× · lower than 74% of 534
- FCF yield-35.9% · higher than 31% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc.🇺🇸 | $343 M | — | — | +622.5% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on September 2020
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Atea Pharmaceuticals, Inc.? Verify and update this profile — free
Show Atea Pharmaceuticals, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.